Stellate Ganglion Blockade With Continuous Infusion Versus SingleInjection for Treatment of Ventricular Arrhythmia Storm.

Abstract

This study sought to compare the efficacy and safety of single-injection stellate ganglion block (SGB) with a novel continuous-infusion SGB procedure. SGB for ventricular arrhythmia (VA) storm is typically performed with a single injection of local anesthetic agents. Eighteen patients underwent left-sided SGB (9 single injection and 9 continuous infusion). The number of implantable cardioverter-defibrillator therapies and sustained VAs/24 h were compared between the pre-SGB and post-SGB periods. Adverse effects of SGB and in-hospital outcomes were also compared. The mean age was 61.1 ± 13.7 years. The presenting arrhythmia was ventricular tachycardia in 13 (72%) patients, ventricular fibrillation in 4 (22%), and both in 1 (6%). Single-injection SGB reduced VA/24h by a median of 0.3 (interquartile range: 0.2 to 0.9), which was a 45% reduction (p=0.008), resulting in 5 of 9 patients with no recurrent VA. Continuous-infusion SGB reduced VA/24h by a median of 2.0 (interquartile range: 1.3 to 3.0), which was a 94% reduction (p=0.004), resulting in 7 of 9 patients with no recurrent VA (p=0.006 for comparison with single injection). Transient left arm weakness and voice hoarseness were each noted in 1 patient in both groups. Repeat SGB was required in 4 (44%) patients in the single-injection group. In-hospital outcomes were similar between the groups. In patients with VA storm, SGB performed via both continuous-infusion and single-injection approaches provided significant reductions in VA burden. Compared to single-injection SGB, continuous-infusion was associated with a greater reduction in VA burden and similar adverse events, without the need for repeat procedures.